TY - JOUR
T1 - Inhibitory effects of gallium chloride and tris (8-quinolinolato) gallium III on A549 human malignant cell line
AU - Collery, Philippe
AU - Lechenault, Francoise
AU - Cazabat, Annie
AU - Khassanova, Lylia
AU - Evangelou, Angelos M.
AU - Keppler, Bernhard
N1 - Coden: ANTRD
Affiliations: Dept. des Maladies Respiratoires, Ho^pital Maison Blanche, 45 rue Cognacq Jay, 51092 Reims Cedex, France; Laboratoire de Physiologie, Ho^pital Maison Blanche, 45 rue Cognacq Jay, 51092 Reims Cedex, France; Dept. of Environmental Protection, Bashkir State University, 32 Frunze Street, 450072 Ufa, Russian Federation; Lab. of Experimental Physiology, Faculty of Medicine, University of Ioannina, 451 10 Ioannina, Greece; Inst. of Gen. and Inorg. Chemistry, Vienna University, Waehringer Str. 42, A-1090 Vienna, Austria; Dept. des Maladies Respiratoires, Ho^pital Maison Blanche, Centre Hospitalier Universitaire, 45, rue Cognaq Jay, 51092 Reims Cedex, France
Adressen: Collery, P.; Departement Maladies Respiratoires; Hopital Maison Blanche; Centre Hospitalier Universitaire; 45 rue Cognaq Jay 51092 Reims cedex, France; email: [email protected]
Source-File: ChemieErgScopus.csv
Import aus Scopus: 2-s2.0-0034010314
Importdatum: 09.01.2007 14:16:06
12.02.2008: Datenanforderung 2112 (Import Sachbearbeiter)
09.02.2010: Datenanforderung UNIVIS-DATEN-DAT.RA-2 (Import Sachbearbeiter)
PY - 2000
Y1 - 2000
N2 - The effects of two gallium (Ga) compounds, Ga chloride (GaCl3) and tris(8-quinolinolato)Ga (III) on the viability of A549 human malignant lung adenocarcinoma cells were investigated. The results demonstrated that both drugs reduced the viability of A549 cells but to different extents. The inhibitory effects of tris(8-quinolinolato)Ga (III) were 10 times more profound than those produced by GaCl3. The IC50 was obtained with 2.5 œM of tris(8-quinolinolato)Ga (III) and 25 œM GaCl3 after an exposure time of 48 hours. Further, whereas the inhibitory effects of GaCl3 were both dose and time-dependent those of tris(8-quinolinolato)Ga (III) appeared to be only dose-dependent, indicating differences in their mechanism of action. Comparison with data drawn from the literature suggests that GaCl3 seems to be in the same range of activity as Ga nitrate or Ga-pyridoxal isocotinoyl hydrazone. Tris(8-quinolinolato)Ga (III) could be as effective as transferrin-Ga, but with the advantage of oral administration and a greater bioavailability of the tris(8-quinolinolato)Ga (III) compound.
AB - The effects of two gallium (Ga) compounds, Ga chloride (GaCl3) and tris(8-quinolinolato)Ga (III) on the viability of A549 human malignant lung adenocarcinoma cells were investigated. The results demonstrated that both drugs reduced the viability of A549 cells but to different extents. The inhibitory effects of tris(8-quinolinolato)Ga (III) were 10 times more profound than those produced by GaCl3. The IC50 was obtained with 2.5 œM of tris(8-quinolinolato)Ga (III) and 25 œM GaCl3 after an exposure time of 48 hours. Further, whereas the inhibitory effects of GaCl3 were both dose and time-dependent those of tris(8-quinolinolato)Ga (III) appeared to be only dose-dependent, indicating differences in their mechanism of action. Comparison with data drawn from the literature suggests that GaCl3 seems to be in the same range of activity as Ga nitrate or Ga-pyridoxal isocotinoyl hydrazone. Tris(8-quinolinolato)Ga (III) could be as effective as transferrin-Ga, but with the advantage of oral administration and a greater bioavailability of the tris(8-quinolinolato)Ga (III) compound.
M3 - Article
SN - 0250-7005
VL - 20
SP - 955
EP - 958
JO - Anticancer Research: International journal of cancer research and treatment
JF - Anticancer Research: International journal of cancer research and treatment
IS - 2 A
ER -